<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SYNERCID- quinupristin and dalfopristin injection, powder, lyophilized, for solution </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<h1>Synercid<span class="Sup">®</span> I.V.<br>(quinupristin and dalfopristin for injection)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_s4"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION </h1>
<p class="First"><span class="Bold">Synercid<span class="Sup">®</span></span> (quinupristin and dalfopristin powder for injection) I.V., a streptogramin antibacterial agent for intravenous administration, is a sterile lyophilized formulation of two semisynthetic pristinamycin derivatives, quinupristin (derived from pristinamycin I) and dalfopristin (derived from pristinamycin IIA) in the ratio of 30:70 (w/w). </p>
<p>Quinupristin is a white to very slightly yellow, hygroscopic powder. It is a combination of three peptide macrolactones. The main component of quinupristin (&gt;88.0%) has the following chemical name: N-[(6<span class="Italics">R</span>,9<span class="Italics">S</span>,10<span class="Italics">R</span>,13<span class="Italics">S</span>,15<span class="Italics">aS</span>,18<span class="Italics">R</span>,22<span class="Italics">S</span>,24<span class="Italics">aS</span> )-22-[<span class="Italics">p</span>-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3<span class="Italics">S</span> )-3-quinuclidinylthio] methyl]-12<span class="Italics">H</span>-pyrido[2,1-<span class="Italics">f</span> ]pyrrolo-[2,1-<span class="Italics">l</span> ][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide. </p>
<p>The main component of quinupristin has an empirical formula of C<span class="Sub">53</span>H<span class="Sub">67</span>N<span class="Sub">9</span>O<span class="Sub">10</span>S, a molecular weight of 1022.24 and the following structural formula: </p>
<div class="Figure"><img alt="ChemStructure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28f698df-b584-4455-2e94-6efc41313960&amp;name=synercid-01.jpg"></div>
<p>Dalfopristin is a slightly yellow to yellow, hygroscopic, powder. The chemical name for dalfopristin is: (3<span class="Italics">R</span>,4<span class="Italics">R</span>,5<span class="Italics">E</span>,10<span class="Italics">E</span>,12<span class="Italics">E</span>,14<span class="Italics">S</span>,26<span class="Italics">R</span>,26a<span class="Italics">S </span>)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3<span class="Italics">H</span>-21,18-nitrilo-1<span class="Italics">H</span>,22<span class="Italics">H</span>-pyrrolo[2,1-<span class="Italics">c</span> ][1,8,4,19]-dioxadiazacyclotetracosine-1,7,16,22(4<span class="Italics">H</span>,17<span class="Italics">H </span>)-tetrone. </p>
<p>Dalfopristin has an empirical formula of C<span class="Sub">34</span>H<span class="Sub">50</span>N<span class="Sub">4</span>O<span class="Sub">9</span>S, a molecular weight of 690.85 and the following structural formula:</p>
<div class="Figure"><img alt="ChemStructure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28f698df-b584-4455-2e94-6efc41313960&amp;name=synercid-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_s5"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Quinupristin and dalfopristin are the main active components circulating in plasma in human subjects. Quinupristin and dalfopristin are converted to several active major metabolites: two conjugated metabolites for quinupristin (one with glutathione and one with cysteine) and one non-conjugated metabolite for dalfopristin (formed by drug hydrolysis). </p>
<p>Pharmacokinetic profiles of quinupristin and dalfopristin in combination with their metabolites were determined using a bioassay following multiple 60-minute infusions of <span class="Bold">Synercid</span> in two groups of healthy young adult male volunteers. Each group received 7.5 mg/kg of <span class="Bold">Synercid</span> intravenously q12h or q8h for a total of 9 or 10 doses, respectively. The pharmacokinetic parameters were proportional with q12h and q8h dosing; those of the q8h regimen are shown in the following table: </p>
<a name="t300"></a><table width="516.000">
<caption><span>Mean Steady-State Pharmacokinetic Parameters of Quinupristin and Dalfopristin in Combination with their Metabolites (± SD<span class="Sup">1</span>) (dose = 7.5 mg/kg q8h; n=10) </span></caption>
<col align="left" width="44.8%">
<col align="left" width="17.1%">
<col align="left" width="18.0%">
<col align="left" width="20.2%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">C</span><span class="Sub">max</span><span class="Sup">2 </span><span class="Bold">(μg/mL)</span>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">AUC</span><span class="Sup">3 </span><span class="Bold">(μg.h/mL)</span>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">t </span><span class="Sub">1/2</span><span class="Sup">4 </span><span class="Bold">(hr)</span>
</td>
</tr></thead>
<tfoot>
<tr><td align="left" colspan="4" valign="top"><p class="First"><span class="Sup">1</span> SD= Standard Deviation </p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First"><span class="Sup">2</span> C<span class="Sub">max</span> = Maximum drug plasma concentration </p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First"><span class="Sup">3</span> AUC = Area under the drug plasma concentration-time curve </p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top"><p class="First"><span class="Sup">4</span> t <span class="Sub">1/2</span> = Half-life </p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold">Quinupristin and metabolites</span></td>
<td class="Toprule" align="center" valign="top">3.20 ± 0.67 </td>
<td class="Toprule" align="center" valign="top">7.20 ± 1.24 </td>
<td align="center" valign="top">3.07 ± 0.51 </td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="Bold">Dalfopristin and metabolite</span></td>
<td align="center" valign="top">7.96 ± 1.30 </td>
<td align="center" valign="top">10.57 ± 2.24 </td>
<td align="center" valign="top">1.04 ± 0.20 </td>
</tr>
</tbody>
</table>
<p>The clearances of unchanged quinupristin and dalfopristin are similar (0.72 L/h/kg), and the steady-state volume of distribution for quinupristin is 0.45 L/kg and for dalfopristin is 0.24 L/kg. The elimination half-life of quinupristin and dalfopristin is approximately 0.85 and 0.70 hours, respectively. </p>
<p>The total protein binding of quinupristin is higher than that of dalfopristin. Synercid does not alter the <span class="Italics">in vitro</span> binding of warfarin to proteins in human serum.</p>
<p>Penetration of unchanged quinupristin and dalfopristin in noninflammatory <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid corresponds to about 19% and 11% of that estimated in plasma, respectively. The penetration into <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid of quinupristin and dalfopristin in combination with their major metabolites was in total approximately 40% compared to that in plasma. </p>
<p><span class="Italics">In vitro</span>, the transformation of the parent drugs into their major active metabolites occurs by non-enzymatic reactions and is not dependent on cytochrome-P450 or glutathione-transferase enzyme activities. </p>
<p><span class="Bold">Synercid</span> has been shown to be a major inhibitor (<span class="Italics">in vitro</span> inhibits 70% cyclosporin A biotransformation at 10 μg/mL of <span class="Bold">Synercid</span>) of the activity of cytochrome P450 3A4 isoenzyme. (See <span class="Bold"><a href="#i4i_warnings_id_s20">WARNINGS.</a></span>) </p>
<p><span class="Bold">Synercid</span> can interfere with the metabolism of other drug products that are associated with QTc prolongation. However, electrophysiologic studies confirm that <span class="Bold">Synercid</span> does not itself induce QTc prolongation. (See <span class="Bold"><a href="#i4i_warnings_id_s20">WARNINGS.</a></span>) </p>
<p>Fecal excretion constitutes the main elimination route for both parent drugs and their metabolites (75 to 77% of dose). Urinary excretion accounts for approximately 15% of the quinupristin and 19% of the dalfopristin dose. Preclinical data in rats have demonstrated that approximately 80% of the dose is excreted in the bile and suggest that in man, biliary excretion is probably the principal route for fecal elimination. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s6"></a><a name="section-2.2"></a><p></p>
<h2>Special Populations </h2>
<p class="First"><span class="Italics">Elderly:</span> The pharmacokinetics of quinupristin and dalfopristin were studied in a population of elderly individuals (range 69 to 74 years). The pharmacokinetics of the drug products were not modified in these subjects. </p>
<p><span class="Italics">Gender:</span> The pharmacokinetics of quinupristin and dalfopristin are not modified by gender. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> In patients with creatinine clearance 6 to 28 mL/min, the AUC of quinupristin and dalfopristin in combination with their major metabolites increased about 40% and 30%, respectively. </p>
<p>In patients undergoing Continuous Ambulatory Peritoneal Dialysis, dialysis clearance for quinupristin, dalfopristin and their metabolites is negligible. The plasma AUC of unchanged quinupristin and dalfopristin increased about 20% and 30%, respectively. The high molecular weight of both components of <span class="Bold">Synercid</span> suggests that it is unlikely to be removed by hemodialysis. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span> In patients with hepatic dysfunction (Child-Pugh scores A and B), the terminal half-life of quinupristin and dalfopristin was not modified. However, the AUC of quinupristin and dalfopristin in combination with their major metabolites increased about 180% and 50%, respectively. (See <span class="Bold"><a href="#i4i_dosage_admin_id_s47">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><a href="#i4i_precautions_id_s22">PRECAUTIONS</a></span>.) </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></span> (body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index ≥30): In obese patients the C<span class="Sub">max</span> and AUC of quinupristin increased about 30% and those of dalfopristin about 40%. </p>
<p><span class="Italics">Pediatric Patients:</span> The pharmacokinetics of <span class="Bold">Synercid</span> in patients less than 16 years of age have not been studied.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_24d447b2-358a-41c4-ad93-2c4532dfc5c6"></a><a name="section-2.3"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The streptogramin components of <span class="Bold">Synercid</span>, quinupristin and dalfopristin, are present in a ratio of 30 parts quinupristin to 70 parts dalfopristin. These two components act synergistically so that <span class="Bold">Synercid's</span> microbiologic <span class="Italics">in vitro</span> activity is greater than that of the components individually. Quinupristin's and dalfopristin's metabolites also contribute to the antimicrobial activity of <span class="Bold">Synercid</span>. <span class="Italics">In vitro</span> synergism of the major metabolites with the complementary parent compound has been demonstrated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e591932-a0d8-4ffb-8407-eb8d3df4ac5d"></a><a name="section-2.4"></a><p></p>
<h2><span class="Underline">Mechanism of Action</span></h2>
<p class="First">The site of action of quinupristin and dalfopristin is the bacterial ribosome. Dalfopristin has been shown to inhibit the early phase of protein synthesis while quinupristin inhibits the late phase of protein synthesis. <span class="Bold">Synercid</span> is bactericidal against isolates of methicillin-susceptible and methicillin-resistant staphylococci. The mode of action of Synercid differs from that of other classes of antibacterial agents such as ß-lactams, aminoglycosides, glycopeptides, quinolones, macrolides, lincosamides and tetracyclines. Therefore, there is no cross resistance between <span class="Bold">Synercid</span> and these agents when tested by the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) method.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa782df9-437c-4588-88bd-69688a892d3b"></a><a name="section-2.5"></a><p></p>
<h2><span class="Underline">Mechanism of Resistance</span></h2>
<p class="First">Resistance to <span class="Bold">Synercid</span> is associated with resistance to both components (<span class="Italics">i.e.</span>, quinupristin and dalfopristin). In non-comparative studies, emerging resistance to <span class="Bold">Synercid </span>has occurred.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dbd635d0-d1d7-46a5-8e4f-be698dcf5614"></a><a name="section-2.6"></a><p></p>
<h2><span class="Underline">Interaction with other Antibacterials</span></h2>
<p class="First"><span class="Italics">In vitro</span> combination testing of <span class="Bold">Synercid</span> with aztreonam, cefotaxime, ciprofloxacin, and gentamicin against <span class="Italics">Enterobacteriaceae</span> and <span class="Italics">Pseudomonas aeruginosa</span> did not show antagonism. </p>
<p><span class="Italics">In vitro</span> combination testing of <span class="Bold">Synercid</span> with prototype drugs of the following classes: aminoglycosides (gentamicin), β-lactams (cefepime, ampicillin, and amoxicillin), glycopeptides (vancomycin), quinolones (ciprofloxacin), tetracyclines (doxycycline) and also chloramphenicol against enterococci and staphylococci did not show antagonism. </p>
<p><span class="Bold">Synercid</span> has been shown to be active against most isolates of the following bacteria, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, as described in the <span class="Bold"><a href="#i4i_indications_id_s17">INDICATIONS AND USAGE</a></span> section. </p>
<p><span class="Bold">Gram-positive bacteria</span><br><span class="Italics">Staphylococcus aureus</span> (methicillin-susceptible isolates only)<br><span class="Italics">Streptococcus pyogenes</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, <span class="Bold">but their clinical significance is unknown.</span></p>
<p>The combination of quinupristin and dalfopristin (<span class="Bold">Synercid</span>) exhibits <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC's) of ≤1.0 μg/mL against most (≥90%) isolates of the following microorganisms; however, the safety and effectiveness of <span class="Bold">Synercid</span> in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well-controlled clinical trials. </p>
<p><span class="Bold">Gram-positive bacteria</span><br><span class="Italics">Corynebacterium jeikeium</span><br><span class="Italics">Staphylococcus aureus</span> (methicillin-resistant isolates)<br><span class="Italics">Staphylococcus epidermidis</span> (including methicillin-resistant isolates)<br><span class="Italics">Streptococcus agalactiae</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s12"></a><a name="section-3"></a><p></p>
<h1>SUSCEPTIBILITY TEST METHODS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s13"></a><a name="section-3.1"></a><p></p>
<h2>Dilution Techniques </h2>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution<span class="Sup">1</span> method (broth or agar) or equivalent using standardized inoculum concentrations, and standardized concentrations of quinupristin/dalfopristin (<span class="Bold">Synercid</span>) in a 30:70 ratio made from powder of known potency. The MIC values are interpreted according to the following criteria: </p>
<a name="t301"></a><table width="478.000">
<col align="left" width="46.0%">
<col align="left" width="54.0%">
<thead>
<tr class="Botrule First"><th align="center" colspan="2" valign="top">For Susceptibility Testing of <span class="Italics">Staphylococcus aureus</span>, and <span class="Italics">Streptococcus pyogenes</span> (excluding <span class="Italics">Streptococcus pneumoniae</span>)<span class="Sup">a.</span>
</th></tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">MIC (μg/mL)</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Interpretation</span></td>
</tr>
</thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="2" valign="top"><p class="First"><span class="Sup">a.</span>The interpretive values for <span class="Italics">Streptococcus pyogenes</span> are applicable only to broth microdilution susceptibility testing using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="center" valign="top">≤1.0 </td>
<td align="center" valign="top">Susceptible (S) </td>
</tr>
<tr>
<td align="center" valign="top">2.0 </td>
<td align="center" valign="top">Intermediate (I) </td>
</tr>
<tr class="Last">
<td align="center" valign="top">≥4.0 </td>
<td align="center" valign="top">Resistant (R) </td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the concentration of the antimicrobial compound in the blood reaches usually achievable levels. A report of "Intermediate" indicates that the result should be considered equivocal, and if the bacterium is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s14"></a><a name="section-3.1.1"></a><p></p>
<h3><span class="Bold">Quality Control</span></h3>
<p class="First">A standardized susceptibility test procedure requires the use of laboratory control bacteria to control the technical aspects of the laboratory procedures. Standard quinupristin/dalfopristin powder in a 30:70 ratio should provide the following MIC values with the indicated quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>: </p>
<a name="id_04fc70d5-3304-4ee1-a5ab-2c68e52191fe"></a><table border="0" width="75%">
<col width="60%">
<col width="40%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Microorganisms (ATCC <span class="Sup">®</span>  #)</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">MIC (μg/mL)</span></td>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="2" valign="top">
<span class="Sup">1.</span> The interpretive values for <span class="Italics">Streptococcus pyogenes</span> are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood when incubated in 5% CO<span class="Sub">2</span>. </td></tr>
<tr class="Last"><td align="left" colspan="2" valign="top">
<span class="Sup">a.</span><span class="Italics"> Streptococcus pneumoniae</span> is used when testing <span class="Italics">Streptococcus pyogenes</span>.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule" align="left" valign="top">
<span class="Italics">Staphylococcus aureus</span> (29213)</td>
<td class="Botrule" align="left" valign="top">0.25 to 1.0</td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<span class="Italics">Streptococcus pneumoniae</span> (49619)<span class="Sup">1 a</span><span class="Italics"><span class="Sup">.</span></span>
</td>
<td align="left" valign="top">0.25 to 1.0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s15"></a><a name="section-3.2"></a><p></p>
<h2>Diffusion Techniques </h2>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">1</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15 μg quinupristin/dalfopristin in a ratio of 30:70 (<span class="Bold">Synercid</span>) to test the susceptibility of bacteria to quinupristin/dalfopristin. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15 μg quinupristin/dalfopristin disk are interpreted according to the following criteria: </p>
<a name="t302"></a><table width="588.000">
<col align="left" width="46.8%">
<col align="left" width="53.2%">
<thead>
<tr class="Botrule First"><th align="center" colspan="2" valign="top">For Susceptibility Testing of <span class="Italics">Staphylococcus aureus</span>, and <span class="Italics">Streptococcus pyogenes</span> (excluding <span class="Italics">Streptococcus pneumoniae</span>)<span class="Sup">b.</span>
</th></tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Zone Diameter (mm)</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Interpretation</span></td>
</tr>
</thead>
<tfoot><tr class="Last"><td class="Botrule Lrule" align="left" colspan="2" valign="top"><p class="First"><span class="Sup">b.</span>The zone diameter for <span class="Italics">Streptococcus pyogenes</span> are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood when incubated in 5% CO<span class="Sub">2</span>. </p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="center" valign="top">≥19 </td>
<td align="center" valign="top">Susceptible (S) </td>
</tr>
<tr>
<td align="center" valign="top">16 to 18 </td>
<td align="center" valign="top">Intermediate (I) </td>
</tr>
<tr class="Last">
<td align="center" valign="top">≤15 </td>
<td align="center" valign="top">Resistant (R) </td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for quinupristin/dalfopristin. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s16"></a><a name="section-3.2.1"></a><p></p>
<h3><span class="Bold">Quality Control</span></h3>
<p class="First">As with standardized dilution techniques, diffusion methods require the use of laboratory control bacteria that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 15 μg quinupristin/dalfopristin (30:70 ratio) disk should provide the following zone diameter with the indicated quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.</p>
<a name="id_b8a5e27f-ca19-4ae9-9f82-85eac244d6da"></a><table width="80%">
<col align="left" width="49.4%">
<col align="left" width="50.6%">
<thead><tr class="First Last">
<td class="Botrule" align="center" valign="top"><span class="Bold">Microorganism (ATCC<span class="Sup">®</span>  #)</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Zone Diameter Range (mm)</span></td>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="2" valign="top">
<span class="Sup">1.</span> The zone diameter for <span class="Italics">Streptococcus pyogenes</span> are applicable only to tests performed using Mueller-Hinton agar supplemented with 5% sheep blood when incubated in 5% CO<span class="Sub">2</span>. </td></tr>
<tr class="Last"><td align="left" colspan="2" valign="top">
<span class="Sup">a. </span><span class="Italics">Streptococcus pneumoniae</span> is used when testing <span class="Italics">Streptococcus pyogenes</span>.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule" align="center" valign="top">
<span class="Italics">Staphylococcus aureus</span> (25923) </td>
<td class="Botrule" align="center" valign="top">21 to 28 </td>
</tr>
<tr class="Last">
<td align="center" valign="top">
<span class="Italics">Streptococcus pneumoniae </span> (49619)<span class="Sup">1 a</span>
</td>
<td align="center" valign="top">19 to 24</td>
</tr>
</tbody>
</table>
<p><span class="Bold">ATCC</span><span class="Sup">® </span><span class="Bold">is a registered trademark of the American Type Culture Collection</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_s17"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<p class="First"><span class="Bold">Synercid</span> is indicated in adults for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms. </p>
<p><span class="Bold">Complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> caused by <span class="Italics">Staphylococcus aureus</span> (methicillin susceptible) or <span class="Italics">Streptococcus pyogenes</span>. (See <span class="Bold"><a href="#i4i_clinical_studies_id_s56">CLINICAL STUDIES.</a></span>) </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_s19"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First"><span class="Bold">Synercid</span> is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to <span class="Bold">Synercid</span>, or with prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other streptogramins (<span class="Italics">e.g.</span>, pristinamycin or virginiamycin). </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_s20"></a><a name="section-6"></a><p></p>
<h1>WARNINGS </h1>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_b864c9c8-cfac-4d2c-9104-ec2bece95302"></a><a name="section-6.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Italics">In vitro</span> drug interaction studies have demonstrated that <span class="Bold">Synercid</span> significantly inhibits cytochrome P450 3A4 metabolism of cyclosporin A, midazolam, nifedipine and terfenadine. In addition, 24 subjects given <span class="Bold">Synercid</span> 7.5 mg/kg q8h for 2 days and 300 mg of cyclosporine on day 3 showed an increase of 63% in the AUC of cyclosporine, an increase of 30% in the C<span class="Sub">max</span> of cyclosporine, a 77% increase in the t<span class="Sub">1/2</span> of cyclosporine, and, a decrease of 34% in the clearance of cyclosporine. <span class="Bold">Therapeutic level monitoring of cyclosporine should be performed when cyclosporine must be used concomitantly with Synercid</span>. </p>
<p><span class="Bold">It is reasonable to expect that the concomitant administration of Synercid and other drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may likely result in increased plasma concentrations of these drugs that could increase or prolong their therapeutic effect and/or increase adverse reactions. (See Table below.) Therefore, coadministration of Synercid with drugs which are cytochrome P450 3A4 substrates and possess a narrow therapeutic window requires caution and monitoring of these drugs (e.g., cyclosporine), whenever possible. Concomitant medications metabolized by the cytochrome P450 3A4 enzyme system that may prolong the QTc interval should be avoided.</span></p>
<p>Concomitant administration of <span class="Bold">Synercid</span> and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The C<span class="Sub">max</span> increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively. </p>
<br><p><span class="Underline">Table of Selected Drugs That Are Predicted to Have Plasma Concentrations Increased by <span class="Bold">Synercid</span> + </span></p>
<p><span class="Italics">Antihistamines:</span> astemizole, terfenadine </p>
<p><span class="Italics">Anti-HIV (NNRTIs and Protease inhibitors):</span> delavirdine, nevirapine, indinavir, ritonavir </p>
<p><span class="Italics">Antineoplastic agents:</span> vinca alkaloids (<span class="Italics">e.g.</span>, vinblastine), docetaxel, paclitaxel </p>
<p><span class="Italics">Benzodiazepines:</span> midazolam, diazepam </p>
<p><span class="Italics">Calcium channel blockers:</span> dihydropyridines (<span class="Italics">e.g.</span>, nifedipine), verapamil, diltiazem </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>-lowering agents:</span> HMG-CoA reductase inhibitors (<span class="Italics">e.g.</span>, lovastatin) </p>
<p><span class="Italics">GI motility agents:</span> cisapride </p>
<p><span class="Italics">Immunosuppressive agents:</span> cyclosporine, tacrolimus </p>
<p><span class="Italics">Steroids:</span> methylprednisolone </p>
<p><span class="Italics">Other:</span> carbamazepine, quinidine, lidocaine, disopyramide </p>
<p>+ This list of drugs is not all inclusive. </p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including <span class="Bold">Synercid</span>, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_s22"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS </h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_s23"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Italics">Venous Irritation:</span> Following completion of a peripheral infusion, the vein should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with 5% Dextrose in Water solution to minimize venous irritation. <span class="Bold">DO NOT FLUSH</span> with saline or heparin <span class="Bold">after Synercid</span> administration because of incompatibility concerns. </p>
<p>If moderate to severe venous irritation occurs following peripheral administration of <span class="Bold">Synercid</span> diluted in 250 mL of Dextrose 5% in water, consideration should be given to increasing the infusion volume to 500 or 750 mL, changing the infusion site, or infusing by a peripherally inserted central catheter (PICC) or a central venous catheter. In clinical trials, concomitant administration of hydrocortisone or diphenhydramine did not appear to alleviate venous <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s24"></a><a name="section-7.1.1"></a><p></p>
<h3>Rate of Infusion</h3>
<p class="First">In animal studies toxicity was higher when <span class="Bold">Synercid</span> was administered as a bolus compared to slow infusion. However, the safety of an intravenous bolus of <span class="Bold">Synercid</span> has not been studied in humans. Clinical trial experience has been exclusively with an intravenous duration of 60 minutes and, thus, other infusion rates cannot be recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s25"></a><a name="section-7.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span>/<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgias</span></h3>
<p class="First">Episodes of <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, some severe, have been reported in patients treated with <span class="Bold">Synercid</span>. In some patients, improvement has been noted with a reduction in dose frequency to q12h. In those patients available for follow-up, treatment discontinuation has been followed by resolution of symptoms. The etiology of these <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span> is under investigation. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s26"></a><a name="section-7.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfections</span></h3>
<p class="First">The use of antibiotics may promote the overgrowth of nonsusceptible organisms. Should <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occur during therapy, appropriate measures should be taken. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s27"></a><a name="section-7.1.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></h3>
<p class="First">Elevations of total bilirubin greater than 5 times the upper limit of normal were noted in approximately 25% of patients in the non-comparative studies. (See<span class="Bold"><a href="#i4i_section_id_s41"> ADVERSE REACTIONS: Non-Comparative Trials.</a></span>) In some patients, isolated <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> (primarily conjugated) can occur during treatment, possibly resulting from competition between <span class="Bold">Synercid</span> and bilirubin for excretion. Of note, in the comparative trials, elevations in ALT and AST occurred at a similar frequency in both the <span class="Bold">Synercid</span> and comparator groups. </p>
<br><p><span class="Bold">Information for Patients</span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_s28"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><span class="Italics">In vitro</span> drug interaction studies have shown that <span class="Bold">Synercid</span> significantly inhibits cytochrome P450 3A4. (See <span class="Bold"><a href="#i4i_warnings_id_s20">WARNINGS</a>.</span>) </p>
<p><span class="Bold">Synercid</span> does not significantly inhibit human cytochrome P450 1A2, 2A6, 2C9, 2C19, 2D6, or 2E1. Therefore, clinical interactions with drugs metabolized by these cytochrome P450 isoenzymes are not expected. </p>
<p>A drug interaction between <span class="Bold">Synercid</span> and digoxin cannot be excluded but is unlikely to occur via CYP3A4 enzyme inhibition. <span class="Bold">Synercid</span> has shown <span class="Italics">in vitro</span> activity (MICs of 0.25 mcg/mL when tested on two <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) against <span class="Italics">Eubacterium lentum.</span> Digoxin is metabolized in part by bacteria in the gut and as such, a drug interaction based on <span class="Bold">Synercid</span>'s inhibition of digoxin's gut metabolism (by <span class="Italics">Eubacterium lentum</span>) may be possible. </p>
<p><span class="Italics">In vitro</span> combination testing of <span class="Bold">Synercid</span> with aztreonam, cefotaxime, ciprofloxacin, and gentamicin, against <span class="Italics">Enterobacteriaceae</span> and <span class="Italics">Pseudomonas aeruginosa</span> did not show antagonism. </p>
<p><span class="Italics">In vitro</span> combination testing of <span class="Bold">Synercid</span> with prototype drugs of the following classes: aminoglycosides (gentamicin), β-lactams (cefepime, ampicillin, and amoxicillin), glycopeptides (vancomycin), quinolones (ciprofloxacin), tetracyclines (doxycycline) and also chloramphenicol against enterococci and staphylococci did not show antagonism. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_s29"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in animals have not been conducted with <span class="Bold">Synercid</span>. Five genetic toxicity tests were performed. <span class="Bold">Synercid</span>, dalfopristin, and quinupristin were tested in the bacterial reverse mutation assay, the Chinese hamster ovary cell HGPRT gene mutation assay, the unscheduled DNA synthesis assay in rat hepatocytes, the Chinese hamster ovary cell chromosome aberration assay, and the mouse micronucleus assay in bone marrow. Dalfopristin was associated with the production of structural chromosome aberrations when tested in the Chinese hamster ovary cell chromosome aberration assay. <span class="Bold">Synercid</span> and quinupristin were negative in this assay. <span class="Bold">Synercid</span>, dalfopristin, and quinupristin were all negative in the other four genetic toxicity assays. </p>
<p>No impairment of fertility or perinatal/postnatal development was observed in rats at doses up to 12 to 18 mg/kg (approximately 0.3 to 0.4 times the human dose based on body-surface area). </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_s30"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic Effects:</span><span class="Italics">Pregnancy Category B</span>: Reproductive studies have been performed in mice at doses up to 40 mg/kg/day (approximately half the human dose based on body-surface area), in rats at doses up to 120 mg/kg/day (approximately 2.5 times the human dose based on body-surface area), and in rabbits at doses up to 12 mg/kg/day (approximately half the human dose based on body-surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to <span class="Bold">Synercid</span>. </p>
<p>There are, however, no adequate and well-controlled studies with <span class="Bold">Synercid</span> in pregnant women. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_s31"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">In lactating rats, <span class="Bold">Synercid</span> was excreted in milk. It is not known whether <span class="Bold">Synercid</span> is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when <span class="Bold">Synercid</span> is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s32"></a><a name="section-7.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Following a single 1-hour infusion of <span class="Bold">Synercid</span> (7.5 mg/kg) to patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, plasma concentrations were significantly increased. (See <span class="Bold"><a href="#i4i_section_id_s6">CLINICAL PHARMACOLOGY: Special Populations.</a></span>) However, the effect of dose reduction or increase in dosing interval on the pharmacokinetics of <span class="Bold">Synercid</span> in these patients has not been studied. Therefore, no recommendations can be made at this time regarding the appropriate dose modification. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_s33"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><span class="Bold">Synercid</span> has been used in a limited number of pediatric patients under emergency-use conditions at a dose of 7.5 mg/kg q8h or q12h. However, the safety and effectiveness of <span class="Bold">Synercid</span> in patients under 16 years of age have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_s34"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In phase 3 comparative trials of <span class="Bold">Synercid</span>, 37% of patients (n=404) were ≥65 years of age, of which 145 were ≥75 years of age. In the phase 3 non-comparative trials, 29% of patients (n=346) were ≥65 years of age, of which 112 were ≥75 years of age. There were no apparent differences in the frequency, type, or severity of related adverse reactions including cardiovascular events between elderly and younger individuals. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_s35"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS </h1>
<p class="First">The safety of <span class="Bold">Synercid</span> was evaluated in 1099 patients enrolled in 5 comparative clinical trials. Additionally, 4 non-comparative clinical trials (3 prospective and 1 retrospective in design) were conducted in which 1199 patients received <span class="Bold">Synercid</span> for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to Gram-positive pathogens for which no other treatment option was available. In non-comparative trials, the patients were severely ill, often with multiple co-morbidities or physiological impairments, and may have been intolerant to or failed other antibacterial therapies. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s36"></a><a name="section-8.1"></a><p></p>
<h2>COMPARATIVE TRIALS </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s37"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">ADVERSE REACTION SUMMARY – ALL COMPARATIVE STUDIES</span></h3>
<p class="First">Safety data are available from five comparative clinical studies (n= 1099 <span class="Bold">Synercid</span>; n= 1095 comparator). One of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the comparative studies was assessed as possibly related to <span class="Bold">Synercid</span>. The most frequent reasons for discontinuation due to drug-related adverse reactions were as follows: </p>
<a name="t303"></a><table width="478.000">
<caption><span>% of patients discontinuing therapy by reaction type </span></caption>
<col align="left" width="39.1%">
<col align="left" width="29.9%">
<col align="left" width="31.0%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Type</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Synercid</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Comparator</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Venous </td>
<td class="Toprule" align="center" valign="top">9.2 </td>
<td align="center" valign="top">2.0 </td>
</tr>
<tr>
<td align="left" valign="top">Non-venous </td>
<td align="center" valign="top">9.6 </td>
<td align="center" valign="top">4.3 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td align="center" valign="top">1.0 </td>
<td align="center" valign="top">0.5 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" valign="top">0.9 </td>
<td align="center" valign="top">0.6 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" valign="top">0.5 </td>
<td align="center" valign="top">0.5 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td align="center" valign="top">0.5 </td>
<td align="center" valign="top">0.0 </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td class="Botrule" align="center" valign="top">0.5 </td>
<td class="Botrule" align="center" valign="top">0.3 </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s38"></a><a name="section-8.1.2"></a><p></p>
<h3><span class="Bold">CLINICAL REACTIONS – ALL COMPARATIVE STUDIES</span></h3>
<p class="First">Adverse reactions with an incidence of ≥1% and possibly or probably related to <span class="Bold">Synercid</span> administration include: </p>
<a name="t304"></a><table width="506">
<col align="left" width="41.3%">
<col align="left" width="30.4%">
<col align="left" width="28.3%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reactions</span></td>
<td class="Botrule" align="center" colspan="2" valign="top">        <span class="Bold"> % of patients with adverse reactions</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Synercid</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Comparator</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> at infusion site </td>
<td class="Toprule" align="center" valign="top">42.0 </td>
<td align="center" valign="top">25.0 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at infusion site </td>
<td align="center" valign="top">40.0 </td>
<td align="center" valign="top">23.7 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> at infusion site </td>
<td align="center" valign="top">17.3 </td>
<td align="center" valign="top">9.5 </td>
</tr>
<tr>
<td align="left" valign="top">Infusion site reaction </td>
<td align="center" valign="top">13.4 </td>
<td align="center" valign="top">10.1 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" valign="top">4.6 </td>
<td align="center" valign="top">7.2 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> </td>
<td align="center" valign="top">2.4 </td>
<td align="center" valign="top">0.3 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center" valign="top">2.7 </td>
<td align="center" valign="top">3.2 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" valign="top">2.7 </td>
<td align="center" valign="top">3.8 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td align="center" valign="top">2.5 </td>
<td align="center" valign="top">1.4 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td align="center" valign="top">1.6 </td>
<td align="center" valign="top">0.9 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td align="center" valign="top">1.5 </td>
<td align="center" valign="top">1.1 </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td class="Botrule" align="center" valign="top">1.5 </td>
<td class="Botrule" align="center" valign="top">0.1 </td>
</tr>
</tbody>
</table>
<p>Additional adverse reactions that were possibly or probably related to <span class="Bold">Synercid</span> with an incidence less than 1% within each body system are listed below: </p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, worsening of underlying illness, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; </p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>; </p>
<p><span class="Bold">Digestive:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>; </p>
<p><span class="Bold">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>; </p>
<p><span class="Bold">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>; </p>
<p><span class="Bold">Nervous:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, vasodilation; </p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>; </p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; </p>
<p><span class="Bold">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s39"></a><a name="section-8.1.3"></a><p></p>
<h3><span class="Bold">CLINICAL REACTIONS – SKIN AND SKIN STRUCTURE STUDIES </span></h3>
<p class="First">In two of the five comparative clinical trials <span class="Bold">Synercid</span> (n=450) and comparator regimens (<span class="Italics">e.g</span>., oxacillin/vancomycin or cefazolin/vancomycin; n=443) were studied for safety and efficacy in the treatment of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The adverse event profile seen in the <span class="Bold">Synercid</span> patients in these two studies differed significantly from that seen in the other comparative studies. What follows is safety data from these two studies. </p>
<p>Discontinuation of therapy was most frequently due to the following drug related events: </p>
<a name="t305"></a><table width="506.000">
<caption><span></span></caption>
<col align="left" width="43.5%">
<col align="left" width="28.3%">
<col align="left" width="28.3%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" colspan="2" valign="top"><span class="Bold">% of patients discontinuing therapy by reaction type</span></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Type</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Synercid</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Comparator</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Venous </td>
<td class="Toprule" align="center" valign="top">12.0 </td>
<td align="center" valign="top">2.0 </td>
</tr>
<tr>
<td align="left" valign="top">Non-venous </td>
<td align="center" valign="top">11.8 </td>
<td align="center" valign="top">4.0 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td align="center" valign="top">2.0 </td>
<td align="center" valign="top">0.9 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" valign="top">1.1 </td>
<td align="center" valign="top">0.0 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" valign="top">0.9 </td>
<td align="center" valign="top">0.0 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td align="center" valign="top">0.9 </td>
<td align="center" valign="top">0.0 </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td class="Botrule" align="center" valign="top">0.9 </td>
<td class="Botrule" align="center" valign="top">0.5 </td>
</tr>
</tbody>
</table>
<p>Venous adverse events were seen predominately in patients who had peripheral infusions. The most frequently reported venous and non-venous adverse reactions possibly or probably related to study drug were: </p>
<a name="t306"></a><table width="478.000">
<col align="left" width="45.8%">
<col align="left" width="27.8%">
<col align="left" width="26.4%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" colspan="2" valign="top"><span class="Bold">% of patients with adverse reactions</span></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Synercid</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Comparator</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">Venous </td>
<td class="Toprule" align="center" valign="top">68.0 </td>
<td align="center" valign="top">32.7 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> at infusion site </td>
<td align="center" valign="top">44.7 </td>
<td align="center" valign="top">17.8 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> at infusion site </td>
<td align="center" valign="top">38.2 </td>
<td align="center" valign="top">14.7 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> at infusion site </td>
<td align="center" valign="top">18.0 </td>
<td align="center" valign="top">7.2 </td>
</tr>
<tr>
<td align="left" valign="top">-Infusion site reaction </td>
<td align="center" valign="top">11.6 </td>
<td align="center" valign="top">3.6 </td>
</tr>
<tr>
<td align="left" valign="top">Non-venous </td>
<td align="center" valign="top">24.7 </td>
<td align="center" valign="top">13.1 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td align="center" valign="top">4.0 </td>
<td align="center" valign="top">2.0 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" valign="top">3.7 </td>
<td align="center" valign="top">1.0 </td>
</tr>
<tr>
<td align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td align="center" valign="top">3.1 </td>
<td align="center" valign="top">1.3 </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">-<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td class="Botrule" align="center" valign="top">3.1 </td>
<td class="Botrule" align="center" valign="top">0.2 </td>
</tr>
</tbody>
</table>
<p>There were eight (1.7%) episodes of thrombus or <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> in the <span class="Bold">Synercid</span> arms and none in the comparator arms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s40"></a><a name="section-8.1.4"></a><p></p>
<h3><span class="Bold">LABORATORY EVENTS-ALL COMPARATIVE STUDIES</span></h3>
<p class="First">The following table shows the number (%) of patients exhibiting laboratory values above or below the clinically relevant "critical" values during treatment phase (with an incidence of 0.1% or greater in either treatment group). </p>
<a name="id_83e17fc5-5c6c-4296-847b-8c9fd9c0e567"></a><table width="510.000">
<col align="left" width="30.2%">
<col align="left" width="26.9%">
<col align="left" width="22.5%">
<col align="left" width="20.4%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="bottom"><span class="Bold">Parameter</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Critically High or<br>Low Value</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Synercid<br>Critically<br>High or Low</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Comparator<br>Critically<br>High or Low</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">AST </td>
<td class="Toprule" align="center" valign="top">&gt; 10 x ULN </td>
<td class="Toprule" align="center" valign="top">9 (0.9) </td>
<td align="center" valign="top">2 (0.2) </td>
</tr>
<tr>
<td align="left" valign="top">ALT </td>
<td align="center" valign="top">&gt; 10 x ULN </td>
<td align="center" valign="top">4 (0.4) </td>
<td align="center" valign="top">4 (0.4) </td>
</tr>
<tr>
<td align="left" valign="top">Total Bilirubin </td>
<td align="center" valign="top">&gt; 5 x ULN </td>
<td align="center" valign="top">9 (0.9) </td>
<td align="center" valign="top">2 (0.2) </td>
</tr>
<tr>
<td align="left" valign="top">Conjugated Bilirubin </td>
<td align="center" valign="top">&gt; 5 x ULN </td>
<td align="center" valign="top">29 (3.1) </td>
<td align="center" valign="top">12 (1.3) </td>
</tr>
<tr>
<td align="left" valign="top">LDH </td>
<td align="center" valign="top">&gt; 5 x ULN </td>
<td align="center" valign="top">10 (2.6) </td>
<td align="center" valign="top">8 (2.1) </td>
</tr>
<tr>
<td align="left" valign="top">Alk Phosphatase </td>
<td align="center" valign="top">&gt; 5 x ULN </td>
<td align="center" valign="top">3 (0.3) </td>
<td align="center" valign="top">7 (0.7) </td>
</tr>
<tr>
<td align="left" valign="top">Gamma-GT </td>
<td align="center" valign="top">&gt; 10 x ULN </td>
<td align="center" valign="top">19 (1.9) </td>
<td align="center" valign="top">10 (1.0) </td>
</tr>
<tr>
<td align="left" valign="top">CPK </td>
<td align="center" valign="top">&gt; 10 x ULN </td>
<td align="center" valign="top">6 (1.6) </td>
<td align="center" valign="top">5 (1.4) </td>
</tr>
<tr>
<td align="left" valign="top">Creatinine </td>
<td align="center" valign="top">≥440 μmoL/L </td>
<td align="center" valign="top">1 (0.1) </td>
<td align="center" valign="top">1 (0.1) </td>
</tr>
<tr>
<td align="left" valign="top">BUN </td>
<td align="center" valign="top">≥35.5 mmoL/L </td>
<td align="center" valign="top">2 (0.3) </td>
<td align="center" valign="top">9 (1.2) </td>
</tr>
<tr>
<td align="left" valign="top">Blood Glucose </td>
<td align="center" valign="top">&gt; 22.2 mmoL/L </td>
<td align="center" valign="top">11 (1.3) </td>
<td align="center" valign="top">11 (1.3) </td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">&lt; 2.2 mmoL/L </td>
<td align="center" valign="top">1 (0.1) </td>
<td align="center" valign="top">1 (0.1) </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonates</span> </td>
<td align="center" valign="top">&gt; 40 mmoL/L </td>
<td align="center" valign="top">2 (0.3) </td>
<td align="center" valign="top">3 (0.5) </td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">&lt; 10 mmoL/L </td>
<td align="center" valign="top">3 (0.5) </td>
<td align="center" valign="top">3 (0.5) </td>
</tr>
<tr>
<td align="left" valign="top">CO<span class="Sub">2</span>
</td>
<td align="center" valign="top">&gt; 50 mmoL/L </td>
<td align="center" valign="top">0 (0.0) </td>
<td align="center" valign="top">0 (0.0) </td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">&lt; 15 mmoL/L </td>
<td align="center" valign="top">1 (0.2) </td>
<td align="center" valign="top">0 (0.0) </td>
</tr>
<tr>
<td align="left" valign="top">Sodium </td>
<td align="center" valign="top">&gt; 160 mmoL/L </td>
<td align="center" valign="top">0 (0.0) </td>
<td align="center" valign="top">0 (0.0) </td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">&lt; 120 mmoL/L </td>
<td align="center" valign="top">5 (0.5) </td>
<td align="center" valign="top">3 (0.3) </td>
</tr>
<tr>
<td align="left" valign="top">Potassium </td>
<td align="center" valign="top">&gt; 6.0 mmoL/L </td>
<td align="center" valign="top">3 (0.3) </td>
<td align="center" valign="top">6 (0.6) </td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">&lt; 2.0 mmoL/L </td>
<td align="center" valign="top">0 (0.0) </td>
<td align="center" valign="top">1 (0.1) </td>
</tr>
<tr>
<td align="left" valign="top">Hemoglobin </td>
<td align="center" valign="top">&lt; 8 g/dL </td>
<td align="center" valign="top">25 (2.6) </td>
<td align="center" valign="top">16 (1.6) </td>
</tr>
<tr>
<td align="left" valign="top">Hematocrit </td>
<td align="center" valign="top">&gt; 60% </td>
<td align="center" valign="top">2 (0.2) </td>
<td align="center" valign="top">0 (0.0) </td>
</tr>
<tr>
<td align="left" valign="top">Platelets </td>
<td align="center" valign="top">&gt; 1,000,000/mm<span class="Sup">3</span>
</td>
<td align="center" valign="top">2 (0.2) </td>
<td align="center" valign="top">2 (0.2) </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">&lt; 50,000/mm<span class="Sup">3</span>
</td>
<td class="Botrule" align="center" valign="top">6 (0.6) </td>
<td class="Botrule" align="center" valign="top">7 (0.7) </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s41"></a><a name="section-8.2"></a><p></p>
<h2>NON-COMPARATIVE TRIALS </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s42"></a><a name="section-8.2.1"></a><p></p>
<h3><span class="Bold">CLINICAL ADVERSE REACTIONS</span></h3>
<p class="First">Approximately one-third of patients discontinued therapy in these trials due to adverse events. However, the discontinuation rate due to adverse reactions assessed by the investigator as possibly or probably related to <span class="Bold">Synercid</span> therapy was approximately 5.0%. </p>
<p>There were three prospectively designed non-comparative clinical trials in patients (n = 972) treated with <span class="Bold">Synercid</span>. One of these studies (301), had more complete documentation than the other two (398A and 398B). The most common events probably or possibly related to therapy were: </p>
<a name="t307"></a><table width="476.000">
<col align="left" width="34.7%">
<col align="left" width="21.8%">
<col align="left" width="21.8%">
<col align="left" width="21.6%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" colspan="3" valign="top"><span class="Bold">% of patients with adverse reaction</span></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Adverse Reactions</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Study 301</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Study 398A</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Study 398B</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td class="Toprule" align="center" valign="top">7.8 </td>
<td class="Toprule" align="center" valign="top">5.2 </td>
<td align="center" valign="top">4.3 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </td>
<td align="center" valign="top">5.1 </td>
<td align="center" valign="top">0.95 </td>
<td align="center" valign="top">3.1 </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </td>
<td align="center" valign="top">7.4 </td>
<td align="center" valign="top">3.3 </td>
<td align="center" valign="top">6.8 </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule" align="center" valign="top">3.8 </td>
<td class="Botrule" align="center" valign="top">2.8 </td>
<td class="Botrule" align="center" valign="top">4.9 </td>
</tr>
</tbody>
</table>
<p>The percentage of patients who experienced severe related <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> was 3.3% and 3.1%, respectively. The percentage of patients who discontinued treatment due to related <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> was 2.3% and 1.8%, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s43"></a><a name="section-8.2.2"></a><p></p>
<h3><span class="Bold">LABORATORY EVENTS </span></h3>
<p class="First">The most frequently observed abnormalities in laboratory studies were in total and conjugated bilirubin, with increases greater than 5 times upper limit of normal, irrespective of relationship to <span class="Bold">Synercid</span>, reported in 25.0% and 34.6% of patients, respectively. The percentage of patients who discontinued treatment due to increased total and conjugated bilirubin was 2.7% and 2.3%, respectively. Of note, 46.5% and 59.0% of patients had high baseline total and conjugated bilirubin levels before study entry. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s44"></a><a name="section-8.2.3"></a><p></p>
<h3><span class="Bold">OTHER</span></h3>
<p class="First">Serious adverse reactions in clinical trials, including non-comparative studies, considered possibly or probably related to <span class="Bold">Synercid</span> administration with an incidence &lt;0.1% include: <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">dysautonomia</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal convulsion</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4162038" conceptname="Occlusion of artery">arterial occlusion</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> syndrome, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. Cases of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> were reported in less than 0.2% of patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s45"></a><a name="section-8.3"></a><p></p>
<h2>Post-marketing Experiences</h2>
<p class="First">In addition to adverse events reported from clinical trials, reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> have been identified during post approval use of <span class="Bold">Synercid</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_s46"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE </h1>
<p class="First">There are four reports of patients receiving <span class="Bold">Synercid</span> doses at up to three times that recommended (7.5 mg/kg). No adverse events were considered possibly or probably related to <span class="Bold">Synercid</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Signs of acute overdosage may include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> as seen in animals given extremely high doses (50 mg/kg) of <span class="Bold">Synercid</span>. Patients who receive an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be carefully observed and given supportive treatment. <span class="Bold">Synercid</span> is not removed by peritoneal dialysis or by hemodialysis. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_s47"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION </h1>
<p class="First"><span class="Bold">Synercid</span> should be administered by intravenous infusion in 5% Dextrose in Water solution over a 60-minute period. (See <span class="Bold"><a href="#i4i_warnings_id_s20">WARNINGS.</a></span>) An infusion pump or device may be used to control the rate of infusion. If necessary, central venous access (<span class="Italics">e.g</span>., PICC) can be used to administer <span class="Bold">Synercid</span> to decrease the incidence of venous irritation. The recommended dosage for the treatment of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is 7.5 mg/kg q12h. The minimum recommended treatment duration for complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is seven days.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s48"></a><a name="section-10.1"></a><p></p>
<h2>Special Populations</h2>
<p class="First"><span class="Italics">Elderly:</span> No dosage adjustment of <span class="Bold">Synercid</span> is required for use in the elderly. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_s5">CLINICAL PHARMACOLOGY: Pharmacokinetics </a></span> and <span class="Bold"><a href="#i4i_precautions_id_s22">PRECAUTIONS: Geriatric Use.</a></span>) </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> No dosage adjustment of <span class="Bold">Synercid</span> is required for use in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or patients undergoing peritoneal dialysis. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_s5">CLINICAL PHARMACOLOGY: Pharmacokinetics.</a></span>) </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span>: Data from clinical trials of <span class="Bold">Synercid</span> suggest that the incidence of adverse effects in patients with chronic liver insufficiency or cirrhosis was comparable to that in patients with normal hepatic function. Pharmacokinetic data in patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child Pugh A or B) suggest that dosage reduction may be necessary but exact recommendations cannot be made at this time. (See <span class="Bold"><a href="#i4i_section_id_s6">CLINICAL PHARMACOLOGY: Special Populations</a></span> and <span class="Bold"><span class="Italics"><a href="#i4i_precautions_id_s22">PRECAUTIONS: General: <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> sections</a></span></span>.) </p>
<p><span class="Italics">Pediatric Patients: </span>The recommended dose of Synercid for pediatric patients (12 to &lt;18 years of age) is 7.5 mg/kg q12h. No dosing recommendations are available in pediatric patients less than 12 years of age. (See <span class="Bold"><a href="#i4i_precautions_id_s22">PRECAUTIONS: Pediatric Use.</a></span>) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s51"></a><a name="section-10.2"></a><p></p>
<h2>Preparation and administration of solution: </h2>
<ol>
<li>Reconstitute the 500 mg single dose vial by slowly adding 5 mL of 5% Dextrose in Water or Sterile Water for injection. </li>
<li>
<span class="Bold">GENTLY</span> swirl the vial by manual rotation without <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> to ensure dissolution of contents while <span class="Bold">LIMITING FOAM FORMATION.</span>
</li>
<li>Allow the solution to sit for a few minutes until all the foam has disappeared. The resulting solution should be clear. Vials reconstituted in this manner will give a solution of 100 mg/mL. <span class="Bold">CAUTION: FURTHER DILUTION REQUIRED BEFORE INFUSION.</span>
</li>
<li>According to the patient's weight, the reconstituted <span class="Bold">Synercid solution</span> should be added to 250 mL of 5% Dextrose solution. An infusion volume of 100 mL may be used for central line infusions. </li>
<li>If moderate to severe venous irritation occurs following peripheral administration of <span class="Bold">Synercid</span> diluted in 250 mL of Dextrose 5% in water, consideration should be given to increasing the infusion volume to 500 or 750 mL, changing the infusion site, or infusing by a peripherally inserted central catheter (PICC) or a central venous catheter. </li>
<li>The desired dose should be administered by intravenous infusion over 60 minutes. </li>
</ol>
<p class="First">NOTE: As for other parenteral drug products, <span class="Bold">Synercid</span> should be inspected visually for particulate matter prior to administration. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s52"></a><a name="section-11"></a><p></p>
<h1>COMPATIBILITY: </h1>
<p class="First"><span class="Bold">DO NOT DILUTE WITH SALINE SOLUTIONS BECAUSE SYNERCID IS NOT COMPATIBLE WITH THESE AGENTS. </span><span class="Bold">Synercid</span> should not be mixed with, or physically added to, other drugs except for the following drugs where compatibility by Y-site injection has been established: </p>
<a name="t308"></a><table width="495.000">
<caption><span>Y-Site Injection Compatibility of Synercid at 2 mg/mL Concentration </span></caption>
<col align="left" width="51.1%">
<col align="left" width="48.9%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"><span class="Bold">Admixture and Concentration</span></td>
<td align="left" valign="top"><span class="Bold">IV Infusion Solutions for Admixture</span></td>
</tr>
<tr>
<td align="left" valign="top">Aztreonam 20 mg/mL </td>
<td align="left" valign="top">D5W </td>
</tr>
<tr>
<td align="left" valign="top">Ciprofloxacin 1 mg/mL </td>
<td align="left" valign="top">D5W </td>
</tr>
<tr>
<td align="left" valign="top">Fluconazole 2 mg/mL </td>
<td align="left" valign="top">Used as the undiluted solution </td>
</tr>
<tr>
<td align="left" valign="top">Haloperidol 0.2 mg/mL </td>
<td align="left" valign="top">D5W </td>
</tr>
<tr>
<td align="left" valign="top">Metoclopramide 5 mg/mL </td>
<td align="left" valign="top">D5W </td>
</tr>
<tr>
<td align="left" valign="top">Potassium Chloride 40 mEq/L </td>
<td align="left" valign="top">D5W </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">D5W = 5% Dextrose Injection </td>
<td class="Botrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>If <span class="Bold">Synercid</span> is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each drug. </p>
<p>With intermittent infusion of <span class="Bold">Synercid</span> and other drugs through a common intravenous line, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> before and after administration with 5% Dextrose in Water solution. </p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_s53"></a><a name="section-11.1"></a><p></p>
<h2>Stability and Storage</h2>
<p class="First"><span class="Bold">Before Reconstitution</span>: The unopened vials should be stored in a refrigerator at 2 to 8°C (36 to 46°F). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s54"></a><a name="section-11.2"></a><p></p>
<h2>Reconstituted and Infusions Solutions</h2>
<p class="First">Because <span class="Bold">Synercid</span> contains no antibacterial preservative, it should be reconstituted under strict aseptic conditions (<span class="Italics">e.g</span>., Laminar Air Flow Hood). The reconstituted solution should be diluted within 30 minutes. Vials are for single use. The storage time of the diluted solution should be as short as possible to minimize the risk of microbial contamination. Stability of the diluted solution prior to the infusion is established as 5 hours at room temperature or 54 hours if stored under refrigeration 2 to 8°C (36 to 46°F). The solution should not be frozen. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_s55"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED </h1>
<p class="First"><span class="Bold">Synercid</span> is supplied as a sterile lyophilized pyrogen-free preparation in single-dose 10 mL type I glass vials with gray elastomeric closure, and aluminum seal with a dark blue flip-off cap for the 500 mg vial. </p>
<a name="id_9f2992e7-426b-4ae8-ae00-638bc57f8fa4"></a><table width="477.000">
<col align="left" width="31.0%">
<col align="left" width="30.0%">
<col align="left" width="27.7%">
<col align="left" width="11.3%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule" align="left" valign="top">
<span class="Bold">NDC</span> 61570-260-10 </td>
<td class="Botrule" align="left" valign="top">Synercid IV 500 mg </td>
<td class="Botrule" align="left" valign="top">150 mg quinupristin and 350 mg dalfopristin </td>
<td class="Botrule" align="left" valign="top">10 vials </td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_s56"></a><a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s59"></a><a name="section-13.1"></a><p></p>
<h2>COMPARATIVE TRIALS </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s60"></a><a name="section-13.1.1"></a><p></p>
<h3><span class="Bold">Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></h3>
<p class="First">Two randomized, open-label, controlled clinical trials of <span class="Bold">Synercid</span> (7.5 mg/kg q12h intravenously [iv]) in the treatment of complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were performed. The comparator drug was oxacillin (2g q6h iv) in the first study (JRV 304) and cefazolin (1g q8h iv) in the second study (JRV 305); however, in both studies vancomycin (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled 450 patients (n = 229 <span class="Bold">Synercid</span>; n= 221 Comparator) and Study JRV 305 enrolled 443 patients (n = 221 <span class="Bold">Synercid</span>; n = 222 Comparator). </p>
<p>In the first study, 105 patients (45.9%) and 106 patients (48.0%) in the <span class="Bold">Synercid</span> and Comparator arms, respectively, were found to be clinically evaluable. For the second study, these values were 113 (51.1%) and 120 (54.1%) patients in the <span class="Bold">Synercid</span> and Comparator arms, respectively. Patients were found not to be clinically evaluable for reasons such as: wrong diagnosis, lower extremity <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> since these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were assumed to include aerobic gram-negative and anaerobic organisms, no specimen for culture obtained, insufficient therapy, no test of cure assessment, etc. </p>
<p>For the patients found to be clinically evaluable, in Study JRV 304 the success rate was 49.5% in the <span class="Bold">Synercid</span> arm and 51.9% in the Comparator arm. In Study JRV 305, the success rates were 66.4% and 64.2% in the <span class="Bold">Synercid</span> and Comparator arms, respectively. </p>
<p>The following table shows the clinical success rate (combined results from two clinical trials) in the clinically evaluable population. Due to the small numbers of patients in the subsets, statistical conclusions could not be reached. </p>
<a name="id_923a1347-8bf9-456e-9b37-6d79e5fb6d57"></a><table width="476.000">
<col align="left" width="40.3%">
<col align="left" width="16.2%">
<col align="left" width="14.9%">
<col align="left" width="13.9%">
<col align="left" width="14.7%">
<thead>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" colspan="4" valign="top"><span class="Bold">Cured or Improved</span></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Type</span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Synercid</span></td>
<td class="Botrule" align="center" colspan="2" valign="top"><span class="Bold">Comparator</span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="center" valign="top">(n/N) </td>
<td class="Toprule" align="center" valign="top">(%) </td>
<td class="Toprule" align="center" valign="top">(n/N) </td>
<td align="center" valign="top">(%) </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138346" conceptname="Erysipelas">Erysipelas</span> (<span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>) </td>
<td align="center" valign="top">52/82 </td>
<td align="center" valign="top">(63.4) </td>
<td align="center" valign="top">43/77 </td>
<td align="center" valign="top">(55.8) </td>
</tr>
<tr>
<td align="left" valign="top">Post-operative <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td align="center" valign="top">14/38 </td>
<td align="center" valign="top">(36.8) </td>
<td align="center" valign="top">24/42 </td>
<td align="center" valign="top">(57.1) </td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Traumatic <span class="product-label-link" type="condition" conceptid="4153877" conceptname="Post-traumatic wound infection">wound infection</span> </td>
<td class="Botrule" align="center" valign="top">33/55 </td>
<td class="Botrule" align="center" valign="top">(60.0) </td>
<td class="Botrule" align="center" valign="top">33/55 </td>
<td class="Botrule" align="center" valign="top">(60.0) </td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_s61"></a><a name="section-14"></a><p></p>
<h1>SAFETY </h1>
<p class="First">Discontinuations of therapy because of adverse reactions which were probably or possibly due to drug therapy occurred more than four times as often in the <span class="Bold">Synercid</span> group than in the comparator group. Approximately half of the discontinuations in the <span class="Bold">Synercid</span> arm were due to venous adverse events. (See <span class="Bold"><a href="#i4i_section_id_s39">ADVERSE REACTIONS: Clinical Reactions: Skin and Skin Structure Studies</a>.</span>) </p>
<p><span class="Bold">Keep out of the reach of children.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_s62"></a><a name="section-15"></a><p></p>
<h1>REFERENCES </h1>
<ol><li>Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial  Susceptibility testing. CLSI document M100-S22. CLSI, 950 West Valley Rd., Suite 2500, Wayne, PA 19807, 2012.</li></ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28f698df-b584-4455-2e94-6efc41313960&amp;name=synercid-02a.jpg"></p>
<p>LAB-0591-3.0</p>
<p>October 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_aef70e26-4c15-4a23-b8be-0cc225622d8a"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mg Vial Label</h1>
<p class="First">NDC 61570-260-01</p>
<p><span class="Bold">Synercid<span class="Sup">®</span> I.V.</span></p>
<p>(quinupristin 150mg and dalfopristin 350mg)<br>for Injection</p>
<p><span class="Bold">500 mg</span></p>
<p>Single Dose Vial, For I.V. Use Only-Not For Direct Infusion<br>1 Sterile Vial</p>
<p><span class="Bold Italics">Pfizer<br>Injectables</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 500 mg Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28f698df-b584-4455-2e94-6efc41313960&amp;name=synercid-03.jpg"></div>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a0f5ddc8-07da-4660-8493-5f4c3f5fa065"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 Vial Carton</h1>
<p class="First">NDC 61570-260-10<br>Contains 10 of NDC 61570-260-01</p>
<p><span class="Bold">REFRIGERATE</span></p>
<p><span class="Bold">Synercid<span class="Sup">®</span> I.V.</span></p>
<p>(quinupristin 150mg and<br>dalfopristin 350mg) for Injection</p>
<p><span class="Bold">500 mg</span></p>
<p>For I.V. Use Only. <span class="Bold">Prior to Reconstitution:</span><br><span class="Bold">Store in a refrigerator 2–8° C (36–46° F).</span><br><span class="Bold">10</span> Single Dose Vials</p>
<p><span class="Bold Italics">Pfizer<br>Injectables</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28f698df-b584-4455-2e94-6efc41313960&amp;name=synercid-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SYNERCID 		
					</strong><br><span class="contentTableReg">quinupristin and dalfopristin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61570-260</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>QUINUPRISTIN</strong> (QUINUPRISTIN) </td>
<td class="formItem">QUINUPRISTIN</td>
<td class="formItem">150 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>DALFOPRISTIN</strong> (DALFOPRISTIN) </td>
<td class="formItem">DALFOPRISTIN</td>
<td class="formItem">350 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61570-260-10</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61570-260-01</td>
<td class="formItem">5 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050748</td>
<td class="formItem">09/21/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">VLG CHEM</td>
<td class="formItem"></td>
<td class="formItem">272606430</td>
<td class="formItem">API MANUFACTURE(61570-260)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Manufacturing Services LLC</td>
<td class="formItem"></td>
<td class="formItem">079415560</td>
<td class="formItem">ANALYSIS(61570-260), LABEL(61570-260), MANUFACTURE(61570-260), PACK(61570-260)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>993b9380-e18d-4b06-b487-b07cfe7008a4</div>
<div>Set id: 28f698df-b584-4455-2e94-6efc41313960</div>
<div>Version: 8</div>
<div>Effective Time: 20140925</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
